Regulatory

Quarterly Report Q2 2021: Preparing Oncoral for the next level

2021-08-19
Download
Presentation
Webcast

Ascelia Pharma AB (publ) (ticker: ACE) today published its quarterly financial report for Q2 2021 (April – June 2021), which is now available on the company’s website: https://www.ascelia.com/ir-media/reports-presentations/

SIGNIFICANT EVENTS IN Q2 2021

  • EGM approval of the directed new share issue
  • Issuance and repurchase of C-shares for share saving program

SIGNIFICANT EVENTS AFTER THE PERIOD

  • Covid-19 impact delays recruitment to SPARKLE study – estimated recruitment timeline could be extended with up to 6 months into H1 2022 (previously H2 2021)
  • FDA conditionally accepted Orviglance® as the brand name for Mangoral
  • Abstract for Orviglance comparison study to gadolinium accepted as an oral paper presentation at the world’s largest radiology conference RSNA

FINANCIAL SUMMARY Q2 2021

  • Operating result of SEK -32.3M (SEK -28.6M)
  • Earnings per share of SEK -0.99 (SEK -1.31)
  • Cash flow from operations of SEK -30.6M (SEK -20.7M)
  • Cash and marketable securities of SEK 319.0M (SEK 144.9M)

 
“We are making steady progress in the ongoing pivotal Phase 3 SPARKLE study. However, the Covid-19 pandemic continues to substantially impact healthcare systems globally, including the conduct of clinical trials. Especially in the U.S., an important country in the SPARKLE study, the increasing infection rates are impacting clinical study activities. In this context, we expect that the recruitment timeline for the SPARKLE study could be extended up to 6 months into H1 2022. Our solid cash position supports operations well into 2023“, said Magnus Corfitzen, CEO at Ascelia Pharma.
 
A presentation for analysts, investors and media will be held today 19 August at 10:00am CET. The event will be hosted by the company’s CEO Magnus Corfitzen, CFO Kristian Borbos, CMO Carl Bjartmar and CCO Julie Waras Brogren. The presentation will be held in English. The presentation can be followed live via the link: https://tv.streamfabriken.com/ascelia-pharma-q2-2021
It will also be possible to take part of the audiocast afterwards at the same address or at Ascelia Pharma’s website: https://www.ascelia.com/ir-media/reports-presentations/

To participate in the telephone conference, please use the dial-in details shown below:
SE: +46 850 558 351
UK: +44 333 3009 265
US: +1 631 9131 422 (pin 44089965#)
DK: +45 781 501 10

2021-09-21

Ascelia Pharma Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the Development of Oncoral in Combination with LONSURF®

Ascelia Pharma AB (publ) (ticker: ACE) today announced that it has signed a clinical collaboration agreement with Taiho Oncology Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. The collaboration concerns an upcoming global Phase 2 clinical study in gastric cancer. In this all-oral combination study, Ascelia Pharma’s irinotecan chemotherapy tablet Oncoral (ASC-201) will be evaluated in combination with Taiho Oncology’s LONSURF® (trifluri ...
2021-08-19

Quarterly Report Q2 2021: Preparing Oncoral for the next level

Ascelia Pharma AB (publ) (ticker: ACE) today published its quarterly financial report for Q2 2021 (April – June 2021), which is now available on the company’s website: https://www.ascelia.com/ir-media/reports-presentations/
2021-08-18

Covid-19 extends recruitment period of SPARKLE study

Ascelia Pharma AB (publ) (ticker: ACE) today announced that the continued global impact of the Covid-19 pandemic could extend the recruitment period of the clinical phase 3 study SPARKLE with up to 6 months. The recruitment is now expected to be completed during H1 2022. Ascelia Pharma has a solid cash position supporting operations well into 2023.